Abstract
Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.
Keywords: Anxiety, anxiolytic-like, cannabis sativa, cannabidiol, CBD, major depression.
Related Books
Advances in Alzheimer's Research
Advances in Alzheimer's Research
Recent Advances in Geriatric Medicine
Recent Advances in Geriatric Medicine
Pain: Causes, Concerns and Consequences
Chemical-Induced Seizures: Mechanisms, Consequences and Treatment
Classical Neurotransmitters and Neuropeptides Involved in Schizoaffective Disorder
Contemporary Sleep Medicine For Patients
Contemporary Sleep Medicine For Physicians
Experimental Stroke
117
